LDHA and primary hyperoxaluria type 1: Recent preclinical work targeting HAO1 [45, 46, 47], and LDHA [48] with adeno‐associated virus (AAV) or LNP‐delivered CRISPR‐Cas9 in PH1 mouse and rat models presented a significant decrease in urinary oxalate accumulation.